<DOC>
	<DOCNO>NCT00027573</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy follow donor peripheral stem cell transplantation treat patient metastatic unresectable kidney cancer .</brief_summary>
	<brief_title>Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Metastatic Unresectable Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall response rate overall disease-free survival patient unresectable metastatic renal cell cancer treat fludarabine cyclophosphamide follow allogeneic peripheral blood stem cell transplantation . - Determine toxicity treatment-related mortality regimen patient . - Determine percentage donor chimerism patient treat regimen .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma ( RCC ) Clear cell papillary RCC Granular tumor sarcomatoid feature No purely sarcomatoid RCC , chromophobic RCC , oncocytoma No transitional cell carcinoma renal pelvis collect system Metastatic unresectable disease At least 1 measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan The following consider measurable : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Primary bladder mass Progressive disease interferon alfa and/or interleukin2 metastatic RCC OR intolerance therapy No prior concurrent CNS metastasis Negative MRI brain within past 28 day Must HLAidentical ( 6/6 ) sibling donor PATIENT CHARACTERISTICS : Age : 60 Performance status : ECOG 01 Life expectancy : More 6 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST great 3 time ULN Renal : Creatinine clearance least 40 mL/min Cardiovascular : LVEF least 45 % MUGA echocardiogram Pulmonary : DLCO great 40 % predict ( correct hemoglobin level ) No symptomatic pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No known hypersensitivity E. coliderived product No uncontrolled diabetes mellitus No active serious infection No concurrent malignancy except nonmelanoma skin cancer malignancy le 30 % risk relapse completion therapy PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent sargramostim ( GMCSF ) Concurrent epoetin alfa allow Chemotherapy : No concurrent chemotherapy Endocrine therapy : At least 28 day since prior hormonal therapy ( e.g. , megestrol , corticosteroid , antiestrogen therapy ) Concurrent steroid allow adrenal failure , graftversushost disease , nondiseaserelated condition ( e.g. , insulin diabetes ) Radiotherapy : At least 14 day since prior radiotherapy Surgery : At least 14 day since prior surgery Other : At least 28 day since prior systemic therapy RCC Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>papillary renal cell carcinoma</keyword>
</DOC>